N/A N=43 Quality Improvement and Personalization for Statins
Cardiovascular Disease
Primary: Percent of Visits Where Moderate-to-high-strength Statins Are Appropriately Initiated — 102; 95 Visits — p=<0.01
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 3 N=911 Clinical Endpoint Study of Ivermectin 0.5% Lotion
Head Lice
Primary: Percentage of Index Participants Who Were Considered a Treatment Success: PP Population — 90.9; 89.0 percentage of participants
N/A N=681,739 Short- and Long-Term Effects of Antibiotics on Childhood Growth
Obesity
Primary: Body Mass Index Z-score Difference at 48-72 Months, Exposed vs. No Antibiotics Less Than 24 Months — 0.04; 0.06; 0.04; 0.07 BMI z-score units
Phase 2 N=224 Phase II Study of Oral Nafithromycin in CABP
Community-Acquired Bacterial Pneumonia (CABP)
Primary: Clinical Response in the ITT Population — 68; 65; 67 Participants
N/A N=67 Comparison of Femoral Tunnel and Clinical Outcome Using Two Anterior Cruciate Ligament Reconstruction Techniques
Rupture of Anterior Cruciate Ligament
Primary: Vascularity of Graft Tendon — 2.5; 4.1 ratio of AUC — p=0.008
N/A N=23 Evaluation of Vision Effects of a Cosmetic Tinted Hydrogel Contact Lens
Refractive Error
Primary: The Binocular Functional Visual Performance Under Distance Day Time Conditions (250 cd/m2) for Centrally Presented High Contrasts (HC) Time Controlled Visual Acuity…
Phase 3 N=375 A Study of Erlotinib in Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer
Non-Small Cell Lung Cancer
Primary: Progression-Free Survival as Assessed by Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1 (v 1.1) — 9.574 months
N/A N=2,018 Mental Imagery Therapy for Autism (MITA) - an Early Intervention Computerized Language Training Program for Children With ASD
Autistic Disorder · Autism · ASD
Primary: Improvement of Language as Measured by Autism Therapy Evaluation Checklist (ATEC) and Mental Synthesis Evaluation Checklist (MSEC). — 8.49; 4.87; 5.03; 3.53 units on a…
Phase 1 N=32 A Study of Oral and Intravenous (IV) Tedizolid Phosphate in Hospitalized Participants, Ages 2 to <12 Years, With Confirmed or Suspected Bacterial Infection (MK-1986-013)
Gram-Positive Bacterial Infections
Primary: Maximum Observed Drug Concentration in Plasma (Cmax) of Tedizolid Phosphate (Prodrug) — 76.3; 82.4; 710; 234 ng/mL
Phase 2 N=120 Trial of Antroquinonol in Patients With Hypercholesterolemia and Hyperlipidemia
Hyperlipidemias
Primary: TG Change (mg/dL ) — -9.2; 14.6; -4.2; -1.3 percentage of change
Phase 2 N=16 Amgen Megakaryopoiesis Protein 2 (AMG 531) in Thrombocytopenic Subjects With Immune Thrombocytopenic Purpura (ITP)
Thrombocytopenic Purpura
Primary: Number of Participants With Adverse Events — 4; 4; 7; 1 Participants
Phase 4 N=12 Reduction in Pain Intensity Following IV or Oral Pain-relieving Products
Pain
Primary: Part 1: Change From Baseline in Pain Intensity at Hour 6 Using the Thermal Suprathreshold Pain in the Ultraviolet-B (UVB) Burn Pain Model — 0.73; -0.64; -0.36; 0.36…
Phase 2 N=17 Efficacy of a Therapeutic Combination of Dronabinol and PEA for Tourette Syndrome
Tourette Syndrome
Primary: Changes in Tic Severity — 7.6 score on a scale
N/A N=38 To Compare Blephapad Combo vs Standard Treatment for Eyelid Cleansing in Bilateral Posterior Blepharitis
Bilateral Blepharitis (Disorder)
Primary: Percentage Change of the Total Score of the Grading Scales for Meibomian Gland Dysfunction (MGD) — -38.5; -29.9 percentage of change in the total score
N/A N=15 Effect of Caloric Restriction and Protein Intake on Metabolism and Anabolic Sensitivity
Weight Loss · Starvation
Primary: Change in Resting Metabolic Rate — -63.4; -77.6; -47.4 kcal change